Exact Sciences Provides Update on Strong Launch Trajectory of Cologuard®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
UPDATE: Mizuho Securities Raises Price Target Following Exact Sciences (EXAS) Positive Test Volume Preannouncement
June 26, 2015 7:51 AM EDT(Updated - June 26, 2015 7:54 AM EDT)
Mizuho Securities reiterates a Buy rating on Exact Sciences (NASDAQ: EXAS), and raised the price target to $35.00 (from $30.00), following positive test volume preannouncement. EXAS reported 21,000 Cologuard tests completed, vs prior estimates of 18,000.
Analyst Peter Lawson... More
Exact Sciences (EXAS) to End Q2 with 21K Completed Cologuard Tests
June 25, 2015 6:39 AM EDTExact Sciences Corp. (Nasdaq: EXAS) today announced that it expects to end the second quarter of 2015 with approximately 21,000 completed Cologuard tests.
More than 13,800 physicians ordered at least one Cologuard test since the October 2014 launch and the patient compliance rate for Cologuard rose to 73 percent.
The company... More
